DPC enters HBV market
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic Products Corp.'s hepatitis B virus test U.S. market entry Aug. 1 more than doubles the Los Angeles firm's infectious disease market potential, company says. The domestic HBV market is estimated at $300-500 mil. DPC entered the U.S. infectious disease market three years ago with tests for rubella, CMV, herpes and toxoplasmosis - a market opportunity less than half that for HBV, according to the firm. On July 31, DPC announced FDA approval of nine in vitro HBV assays for use on the Immulite and Immulite 2000 automated, chemiluminescent platforms, including two HBsAg, one HBsAg confirmatory, two Anti-HBs, two Anti-HBc and two Anti-HBc IgM tests...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.